Navigation Links
Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
Date:12/1/2008

CARLSBAD, Calif., Dec. 1 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:

    What:   New findings published in the journal Nature on the role of a
            microRNA, known as miR-21, in heart failure

    When:   Monday, December 1, 2008, at 8:30 a.m. ET / 5:30 a.m. PT

    Where: http://www.isispharm.com

    How:    Live on the Internet.  Simply log onto our website listed above.

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at http://www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
2. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
3. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
4. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
5. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
7. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
8. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
9. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
10. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
11. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... June 26, 2017 , ... NDA Partners Chairman ... Director of Product Development R&D at Allergan and CMC expert with more than ... and established biopharma companies, has joined the firm as an Expert Consultant. ...
(Date:6/23/2017)... Frederick, MD (PRWEB) , ... June 23, 2017 ... ... laboratory software solutions provider, announced the latest version of LimitLIS®, its rapidly growing ... designed to speed up user adoption, ensure installation integrity, and provide more customization ...
(Date:6/22/2017)... ... June 21, 2017 , ... RMC Pharmaceutical Solutions, Inc. ... Timothy Reinhardt to manage the new site. , Tim has 25 years of ... most recent role as the Director of Manufacturing and Supplier Quality Assessment. ...
(Date:6/22/2017)... (PRWEB) , ... June 22, 2017 , ... ... superior results to clients throughout the biopharma and life sciences industries, continue to ... industry is seeing. Tunnell’s Kip Wolf will be speaking on “The State of ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
Breaking Biology News(10 mins):